Covered recipient · General Payments record
CHARLES PLIMPTON
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$164.80
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $164.80 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Hologic Sales and Service, LLC | $158.18 | 2 |
| Aspira Women's Health Inc | $6.62 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHARLES PLIMPTON
NPI 1891777835 · CMS profile ID 267685
Allopathic & Osteopathic Physicians / Obstetrics & Gynecology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891777835?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891777835?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891777835?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891777835?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $164.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Hologic Sales and Service, LLC | $118.64 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1084918518 | CMS |
| Hologic Sales and Service, LLC | $39.54 | 10/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1084918510 | CMS |
| Aspira Women's Health Inc | $6.62 | 06/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126779710 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $280,140.77 | 30 |
| PY2024 | Principal investigator | $631,342.46 | 58 |
| PY2023 | Principal investigator | $604,319.86 | 129 |
| PY2022 | Principal investigator | $1,688,412.68 | 133 |
| PY2021 | Principal investigator | $3,601,852.60 | 159 |
| PY2020 | Principal investigator | $853,852.30 | 65 |
| PY2019 | Principal investigator | $195,210.58 | 10 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
129 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $28,443.08 | 12/31/2023 | Non-covered Recipient Entity Velocity Clinical Research, Phoenix | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety,Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Riskof Pneumococcal Disease | No dispute reported | 06/30/2026 | 1042488993 |
| Principal investigator 1 | ModernaTX, Inc. | $104.00 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1040222247 |
| Principal investigator 1 | ModernaTX, Inc. | $9,600.00 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222347 |
| Principal investigator 1 | ModernaTX, Inc. | $1,823.90 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222373 |
| Principal investigator 1 | ModernaTX, Inc. | $50.54 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222385 |
| Principal investigator 1 | ModernaTX, Inc. | $750.26 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222399 |
| Principal investigator 1 | ModernaTX, Inc. | $1,051.70 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222411 |
| Principal investigator 1 | ModernaTX, Inc. | $6,708.00 | 12/22/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 | No dispute reported | 06/30/2026 | 1040222493 |
| Principal investigator 1 | ModernaTX, Inc. | $1,495.59 | 12/22/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002963 |
| Principal investigator 1 | PFIZER INC. | $2,227.50 | 12/22/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046381609 |
| Principal investigator 1 | ModernaTX, Inc. | $598.00 | 12/06/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1040220967 |
| Principal investigator 1 | ModernaTX, Inc. | $877.50 | 12/06/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1040221361 |
| Principal investigator 1 | PFIZER INC. | $1,161.60 | 11/23/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045872977 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $900.00 | 11/21/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789714 |
| Principal investigator 1 | ModernaTX, Inc. | $1,470.88 | 11/17/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002897 |
| Principal investigator 1 | Organon LLC | $249.00 | 11/17/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090965 |
| Principal investigator 1 | Organon LLC | $152.00 | 11/17/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016123899 |
| Principal investigator 1 | ModernaTX, Inc. | $39.00 | 11/10/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002891 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 11/08/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002265 |
| Principal investigator 1 | Organon LLC | $152.00 | 11/03/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016127975 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $75.00 | 11/02/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789712 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $225.00 | 11/02/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789716 |
| Principal investigator 1 | ModernaTX, Inc. | $780.00 | 10/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002773 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 10/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002785 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 10/26/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT | No dispute reported | 06/30/2026 | 1127789706 |
| Principal investigator 1 | ModernaTX, Inc. | $1,105.33 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002791 |
| Principal investigator 1 | Organon LLC | $1,910.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090163 |
| Principal investigator 1 | Organon LLC | $885.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090173 |
| Principal investigator 1 | Organon LLC | $885.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090183 |
| Principal investigator 1 | Organon LLC | $885.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090193 |
| Principal investigator 1 | Organon LLC | $885.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090203 |
| Principal investigator 1 | Organon LLC | $1,910.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090215 |
| Principal investigator 1 | Organon LLC | $1,910.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090225 |
| Principal investigator 1 | Organon LLC | $885.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090235 |
| Principal investigator 1 | Organon LLC | $712.00 | 10/25/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016090245 |
| Principal investigator 1 | PFIZER INC. | $2,323.20 | 10/25/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045870733 |
| Principal investigator 1 | PFIZER INC. | $3,484.80 | 10/18/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045870745 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 10/17/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243551 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,000.00 | 10/17/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243557 |
| Principal investigator 1 | ModernaTX, Inc. | $85.00 | 10/13/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002191 |
| Principal investigator 1 | ModernaTX, Inc. | $209.95 | 10/13/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002779 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $281.16 | 10/12/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789704 |
| Principal investigator 1 | ModernaTX, Inc. | $1,100.38 | 09/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002767 |
| Principal investigator 1 | PFIZER INC. | $1,161.60 | 09/23/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045865827 |
| Principal investigator 1 | ModernaTX, Inc. | $12,528.75 | 09/20/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002711 |
| Principal investigator 1 | Organon LLC | $7,416.00 | 09/20/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016080553 |
| Principal investigator 1 | ModernaTX, Inc. | $8,684.00 | 09/13/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002705 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 09/01/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002165 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/01/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002171 |
| Principal investigator 1 | ModernaTX, Inc. | $1,300.00 | 09/01/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002717 |
| Principal investigator 1 | Organon LLC | $1,000.00 | 08/28/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016087753 |
| Principal investigator 1 | Organon LLC | $750.00 | 08/28/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016087763 |
| Principal investigator 1 | Organon LLC | $550.00 | 08/28/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016087773 |
| Principal investigator 1 | Organon LLC | $1,000.00 | 08/28/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016087785 |
| Principal investigator 1 | ModernaTX, Inc. | $955.50 | 08/25/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040215863 |
| Principal investigator 1 | PFIZER INC. | $7,900.00 | 08/25/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046422333 |
| Principal investigator 1 | PFIZER INC. | $1,161.60 | 08/24/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045913435 |
| Principal investigator 1 | ModernaTX, Inc. | $3,208.53 | 08/23/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002371 |
| Principal investigator 1 | Organon LLC | $89,568.90 | 08/23/2023 | Non-covered Recipient Entity Velocity Clinical Research Inc. | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016119099 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 08/22/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1006243569 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,750.00 | 08/16/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1006243563 |
| Principal investigator 1 | ModernaTX, Inc. | $535.20 | 08/16/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040214621 |
| Principal investigator 1 | ModernaTX, Inc. | $1,151.02 | 08/16/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002129 |
| Principal investigator 1 | ModernaTX, Inc. | $955.50 | 08/11/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040214565 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 08/08/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1006243545 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $7,938.00 | 08/02/2023 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094507 |
| Principal investigator 1 | ModernaTX, Inc. | $1,506.70 | 08/02/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040213667 |
| Principal investigator 1 | ModernaTX, Inc. | $432.25 | 07/28/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040213517 |
| Principal investigator 1 | ModernaTX, Inc. | $18.52 | 07/26/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040213469 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1040204171 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1040206637 |
| Principal investigator 1 | ModernaTX, Inc. | $3,185.00 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040213409 |
| Principal investigator 1 | ModernaTX, Inc. | $11,016.85 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040213425 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1040213791 |
| Principal investigator 1 | ModernaTX, Inc. | $2,190.00 | 07/19/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1040223369 |
| Principal investigator 1 | PFIZER INC. | $6,111.60 | 07/14/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045910949 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,745.37 | 07/13/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | No dispute reported | 06/30/2026 | 1127789724 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $2,870.00 | 07/12/2023 | Non-covered Recipient Entity Velocity Clinic Rsrch | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094505 |
| Principal investigator 1 | PFIZER INC. | $3,049.20 | 07/11/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045906561 |
| Principal investigator 1 | ModernaTX, Inc. | $455.00 | 07/07/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040212281 |
| Principal investigator 1 | ModernaTX, Inc. | $23,308.67 | 07/05/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040212209 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,000.00 | 06/27/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789708 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 06/27/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789710 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 06/27/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789720 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 06/23/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040206561 |
| Principal investigator 1 | ModernaTX, Inc. | $6,290.00 | 06/23/2023 | Non-covered Recipient Entity ClinEdge, LLC - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1040223251 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 06/16/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045915065 |
| Principal investigator 1 | PFIZER INC. | $33,987.60 | 06/14/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045904445 |
| Principal investigator 1 | ModernaTX, Inc. | $938.60 | 06/07/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002121 |
| Principal investigator 1 | PFIZER INC. | $3,775.20 | 06/03/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045908983 |
| Principal investigator 1 | PFIZER INC. | $219.38 | 06/03/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046497441 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $3,750.00 | 05/24/2023 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094843 |
| Principal investigator 1 | PFIZER INC. | $4,936.80 | 05/19/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045918735 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,654.29 | 05/17/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243539 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,065.04 | 05/17/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1006243575 |
| Principal investigator 1 | ModernaTX, Inc. | $308.75 | 05/03/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002115 |
| Principal investigator 1 | ModernaTX, Inc. | $6,088.55 | 05/01/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002099 |
| Principal investigator 1 | PFIZER INC. | $1,452.00 | 04/27/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045917621 |
| Principal investigator 1 | PFIZER INC. | $1,417.50 | 04/22/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046473001 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,084.54 | 04/11/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789718 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,084.54 | 04/11/2023 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE | No dispute reported | 06/30/2026 | 1127789722 |
| Principal investigator 1 | PFIZER INC. | $6,534.00 | 03/31/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045919149 |
| Principal investigator 1 | PFIZER INC. | $5,808.00 | 03/30/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045916959 |
| Principal investigator 1 | PFIZER INC. | $3,240.00 | 03/25/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046457227 |
| Principal investigator 1 | ModernaTX, Inc. | $3,001.05 | 03/24/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002109 |
| Principal investigator 1 | PFIZER INC. | $10,018.80 | 03/04/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045917949 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,000.00 | 03/03/2023 | Non-covered Recipient Entity Medpharmics | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094053 |
| Principal investigator 1 | ModernaTX, Inc. | $2,156.38 | 02/24/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002085 |
| Principal investigator 1 | PFIZER INC. | $8,857.20 | 02/24/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045903169 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $13,613.00 | 02/23/2023 | Non-covered Recipient Entity Medpharmics | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094055 |
| Principal investigator 1 | ModernaTX, Inc. | $5,140.52 | 02/22/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002079 |
| Principal investigator 1 | ModernaTX, Inc. | $2,684.82 | 02/10/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002073 |
| Principal investigator 1 | PFIZER INC. | $23,812.80 | 02/09/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045919297 |
| Principal investigator 1 | ModernaTX, Inc. | $455.00 | 02/08/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002067 |
| Principal investigator 1 | PFIZER INC. | $11,260.36 | 02/04/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046470785 |
| Principal investigator 1 | ModernaTX, Inc. | $669.99 | 02/01/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1042002093 |
| Principal investigator 1 | ModernaTX, Inc. | $5,061.88 | 01/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002055 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 01/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002061 |
| Principal investigator 1 | ModernaTX, Inc. | $2,190.00 | 01/27/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002365 |
| Principal investigator 1 | PFIZER INC. | $54,401.12 | 01/27/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS | No dispute reported | 06/30/2026 | 1046547053 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $386.10 | 01/25/2023 | Non-covered Recipient Entity MEDPHARMICS LLC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243525 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $5,510.00 | 01/25/2023 | Non-covered Recipient Entity Medpharmics | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986094057 |
| Principal investigator 1 | ModernaTX, Inc. | $11,596.65 | 01/25/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002047 |
| Principal investigator 1 | ModernaTX, Inc. | $1,840.15 | 01/20/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1042002103 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $193.05 | 01/18/2023 | Non-covered Recipient Entity MEDPHARMICS LLC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243531 |
| Principal investigator 1 | ModernaTX, Inc. | $1,352.33 | 01/18/2023 | Non-covered Recipient Entity Velocity Clinical Research - Phoenix - PPDS | A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | No dispute reported | 06/30/2026 | 1042002041 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,969.80 | 01/11/2023 | Non-covered Recipient Entity MEDPHARMICS LLC | A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA | No dispute reported | 06/30/2026 | 1006243315 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,668.94 | 01/11/2023 | Non-covered Recipient Entity MEDPHARMICS LLC | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR | No dispute reported | 06/30/2026 | 1006243321 |
| Principal investigator 1 | PFIZER INC. | $15,700.00 | 01/06/2023 | Non-covered Recipient Entity MedPharmics LLC | A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1046371913 |